Formulations for AAV gene therapy

Formulations with sugars, buffers, and surfactants stabilize AAV particles across varying temperatures, addressing stability issues and enabling alternative storage options.

JP2025533988APending Publication Date: 2025-10-09MEIRAGTX UK LTD
0 Cites 0 Cited by

Patent Information

Application Number
JP2025521086
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-11
Filing Date
2023-10-11
Publication Date
2025-10-09

AI Technical Summary

Technical Problem

AAV gene therapies are not stable at refrigeration temperatures and freezing processes compromise product quality, limiting delivery options and increasing costs.

Method used

Formulations comprising sugars, buffers, salts, and surfactants, such as trehalose, polysorbate 80, and sodium chloride, maintain AAV viability and infectivity across various temperatures, including ambient to -80°C, and withstand multiple freeze/thaw cycles.

Benefits of technology

Stabilizes AAV particles over extended periods and multiple freeze/thaw cycles, reducing reliance on cold chains and enhancing product accessibility and manufacturability.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A composition for preserving and maintaining viral viability, comprising a balance of ionic strength and osmolality, that results in reproducible and stable product quality at room temperature, 4°C, and has the ability to withstand 10 freeze / thaw events.
Need to check novelty before this filing date? Find Prior Art